Quizzes & Surveys Archive - ESGO CongressESGO Congress

Home
Qsm_quizs

Welcome to the third round of the ESGO 2025 Quiz

focused on Diagnostics and Biomarkers.

Put Your Knowledge To The Test and See How You Measure Up!

Let’s start.

Is biomarker testing essential for the indication of

all ADCs with clinical benefit in gynaecologial cancers?

No, testing is not required for any of the ADCs.

Yes, testing for high expression of the biomarker is essential for all ADCs.

Yes, testing for at least low/medium expression of the biomarker is essential for all ADCs.

No, some biomarkers have such a high prevalence in gynaecological cancers that testing is not necessary.

None

1 out of 3

Is ICG alone the best tracer to

detect SLN in ovarian cancer?

Yes, ICG is the best cost-effective tracer.

No, ICG alone has been demonstrated not to have the best detection rate.

Yes, as other tracer have demonstrated significant rates of adverse events.

No, ICG creates peritoneal spillage in majority of cases.

None

2 out of 3

Can we give contraception during surveillance

after treatment for molar pregnancy?

No, because pregnancy can be achieved immediately following 2 consecutive negative hCG tests.

No, because contraception might interfere with the possibility of recurrence.

Yes, as it is important to perform an hCG surveillance for at least 6 months prior to achieving pregnancy.

Yes, as it can help reduce recurrence rates.

None

3 out of 3

Any comments you wish to share?

Please fill in the comment box below.

Kindly fill in your details and submit your answers to reveal the results.

Name

Country

Time's up

ESGO 2025 Congress

ESGO's International meeting is Europe's landmark meeting in Gynaecological Oncology and the core of ESGO's educational activities.

Held annually, ESGO congress offers professionals a unique opportunity to learn and discuss the latest medical and scientific developments in gynaecological cancers research, treatment and care, as well as to network with key opinion leaders and peers from around the world.